Evidence map›Paper›PMID 19389461›Full record

ArticleMolecular and cellular endocrinology2009

Specificity protein-1 and -3 trans-activate the ovine placental lactogen gene promoter.

K M Jeckel, S W Limesand, R V Anthony

Abstract read
In one paragraph

Article in Molecular and cellular endocrinology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

K M JeckelDepartment of Biomedical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1683, USA.
S W Limesand
R V Anthony
Colorado State University · US

Funding

Early Placental Development in IUGR PregnanciesR01HD043089 · NICHD · UNIVERSITY OF COLORADO DENVER · PI ANTHONY, RUSSELL V · 2005 to 2008
$1.2M
NICHD NIH HHS 5R01HD43089NICHD NIH HHS R01 HD043089
6 · The paper itself

Abstract

The proximal promoter (-383/+16) of the ovine placental lactogen (oPL) gene provides trophoblast-specific expression in vitro. Footprint 6 (FP6; -319/-349) lies within this region, and transfection of two-base pair mutations across FP6 into BeWo cells identified potential binding sites for CCAAT-enhancer binding protein (CEBP) and specificity proteins (Sp). Transfection of CEBP dominant negative or over-expression constructs did not impact transactivation of the proximal promoter. However, Sp1 and Sp3 over-expression constructs increased (p<or=0.05) transactivation. Additionally, Sp1 and Sp3 short-hairpin RNA constructs reduced (p<or=0.01) transactivation of the proximal promoter. In EMSA supershift assays, Sp1 and Sp3 antibodies were able to inhibit migration of the complexes formed with nuclear extracts from BeWo cells and ovine chorionic binucleate cells (oBNC). Furthermore, Southwestern analysis of oBNC nuclear extracts identified a nuclear protein corresponding with Sp3, identified by Western analysis. In conclusion, these results indicate that Sp1 and Sp3 are capable of interacting with FP6 of the oPL gene proximal promoter and function to enhance its transactivation.

Indexed as

Promoter Regions, GeneticAnimalsBlotting, WesternCCAAT-Enhancer-Binding ProteinsCell LineDNA FootprintingElectrophoretic Mobility Shift AssayHumansMutationPlacental LactogenProtein BindingReproducibility of ResultsSheepSp1 Transcription FactorSp3 Transcription FactorTranscriptional ActivationCCAAT-Enhancer-Binding ProteinsPlacental LactogenSp1 Transcription FactorSp3 Transcription Factor

Identifiers

PMID19389461
PMCPMC2700009
OpenAlexW2080269332

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.